Letter: Trials of the HIB vaccine
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Sir: Bernard Dixon's profile (Microbe of the Month, 8 February) of the meningitis bacterium Haemophilus influenzae type b (HIB) appropriately pays tribute to 'the companies that have introduced the vaccine' and ends in a journalistic coda, 'it need be a killer no more'.
What the public may not know is that the extent of the HIB problem was not known until the initiative and hard work of microbiologists in Wales and the Oxford region revealed that at least one child in every 600 had a serious illness caused by HIB infection.
Once the extent of the problem had been documented, it was important to ensure that the recently developed HIB vaccine was safe and effective in UK children. This was achieved by the contribution of many in the Oxford region: immunisation co-ordinators, general practitioners, health visitors, practice nurses and, last but not least, the parents and children who participated in controlled trials, which demonstrated that HIB vaccine gives a high level of protection against meningitis.
This work was conducted with private funding, which made it an independent assessment of proposed government policy. Unfortunately, this independence can lead to complications, as we have encountered in the system of payment to GPs for vaccines given in a research study.
We are concerned that the Department of Health has not yet agreed to pay GPs for vaccinations given before October 1992, despite these vaccinations being due sooner or later in any case. This sort of difficulty has serious implications for the very necessary trials of preventive medicine.
It would be pleasing if the inadequacies of public health resources for the prevention of infectious diseases in the UK, highlighted by the experience with HIB, were recognised and appropriate action was taken.
Yours sincerely,
E. RICHARD MOXON, Department of Paediatrics, University of Oxford; RICHARD T. MAYON-WHITE, Consultant Public Health Physician, Oxfordshire Health Authority;
ROBERT BOOY, Department of Paediatrics, University of Oxford
Oxford
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments